Information on the total number of voting rights and shares comprising the share capital

▤ Summary

OSE Immunotherapeutics reports the total number of voting rights and shares composing its capital as of May 31, 2026. The notice is a standard legal and market disclosure required under French securities rules. The company describes itself as a clinical-stage biotechnology business developing first-in-class therapies in immuno-oncology and immuno-inflammation. The announcement does not describe a new product, financing round, acquisition, or management change.

▦ Linked Companies